Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754567 | 0.86 | HCRTR2 (0.40) | MEN1GAAKMT2AEPHX1TDP1 | |
| SCHEMBL12070332 | 0.86 | HCRTR2 (0.40) | MEN1GAAKMT2AEPHX1TDP1 | |
| SCHEMBL1266666 | 0.86 | HCRTR2 (0.40) | MEN1GAAKMT2AEPHX1TDP1 | |
| SCHEMBL9066092 | 0.80 | SLC6A2 (0.50) | BRD4SLC6A2SLC6A4RAF1BRAF | |
| SCHEMBL590365 | 0.79 | TDP1 (0.49) | MEN1GAAKMT2AEPHX1TDP1 | |
| SCHEMBL15795818 | 0.79 | BRD4 (0.39) | BRD4SLC6A2SLC6A4RAF1BRAF | |
| SCHEMBL22644684 | 0.77 | HCRTR2 (0.38) | MEN1KMT2AEPHX1HCRTR2NPSR1 | |
| SCHEMBL10963876 | 0.77 | SLC6A2 (0.43) | MEN1KMT2ABRD4SLC6A2SLC6A4 | |
| SCHEMBL31252251 | 0.77 | IDO1 (0.43) | — | |
| SCHEMBL5969026 | 0.76 | TDP1 (0.49) | MEN1GAAKMT2AEPHX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
| CN-110691784-B | Compounds for inhibiting MCL-1 protein | 美国安进公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| EP-3587420-B1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| CN-110691784-A | Compounds that inhibit MCL-1 protein | 美国安进公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-104968656-B | autotaxin inhibitors | 诺华股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | MEN1 2423/4885GAA 4013/4885KMT2A 4589/4885 |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | SLC10A1, NR1H4, HAVCR2 | MEN1 2347/4885GAA 1260/4885KMT2A 3253/4885 |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | MEN1 2322/4885GAA 2563/4885KMT2A 244/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | MEN1 2347/4885GAA 1260/4885KMT2A 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.